Association of Genetic Polymorphisms with Histological Grading of Necroinflammation,Staging of Fibrosis,and Liver Function in Mexicans with Chronic Hepatitis C Virus Infection
Restricted accessResearch articleFirst published online October, 2013
Association of Genetic Polymorphisms with Histological Grading of Necroinflammation,Staging of Fibrosis,and Liver Function in Mexicans with Chronic Hepatitis C Virus Infection
The aim of this work was to establish an association between the single-nucleotide polymorphisms (SNPs) of TGFB1 (rs1800471), AT (rs3789679), MMP-1 (rs17886084), MMP-3 (rs35068180), and PAI-1 (rs1799889) and the histological grading of necroinflammation, staging of hepatic fibrosis, and liver function in Mexican patients with advanced liver fibrosis due to chronic hepatitis C virus infection.
Methods
AT, MMP-1, MMP-3, and PAI-1 gene polymorphisms were analyzed by polymerase chain reaction in real time, whereas TGFB1 polymorphism was detected by polymerase chain reaction–based restriction fragment length polymorphism in 38 patients with established advanced liver fibrosis and 50 subjects from the general population. Grading of necroinflammation and staging of liver fibrosis were assessed by liver biopsy and graded according to modified histological activity index Ishak score.
Results
Regarding TGFB1 SNP, significant differences were found between G/G and G/C genotypes of patients with hepatic necroinflammation (P = 0.05) and hepatic fibrosis (P = 0.002). There were also significant differences among genotypes of patients with the AT SNP in hepatic necroinflammation (P = 0.01). The albumin-globulin ratio between genotypes of patients with the MMP-3 SNP gene showed significant differences (P = 0.02).
Conclusion
Our findings demonstrate that a specific combination of genotypes associated with biochemical values and a histological high score determine more severe liver disease. The presence of the G/G genotype of TGFB1 SNP in patients was significantly associated with severity of liver necroinflammation and fibrosis. Patients with the G/G genotype of AT SNP were associated with severe necroinflammation. The albumin-globulin ratio was increased in patients with the 6A allele of MMP-3 SNP. These results might contribute to diagnosis and further establishment of liver disease treatment.
PowellEE, EdwardsCJ, HayJL, . Host genetic factors influence disease progression in chronic hepatitis C. Hepatology. 2000; 31 (4): 828–833.
2.
BatallerR, NorthKE, BrennerDA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology. 2003; 37: 493–503.
3.
DixonJB, BhathalPS, JonssonJR, . Pro fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol. 2003; 39: 967–971.
4.
RichardsonMM, PowellEE, BarrieHD, . A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. J Med Genet. 2005; 42: e45.
5.
DuvnjakM, BarsicN, TomasicV, . Genetic polymorphisms in non-alcoholic fatty liver disease: clues to pathogenesis and disease progression. World J Gastroenterol. 2009; 15: 6023–6027.
6.
HottaK, YonedaM, HyogoH, . Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of non-alcoholic fatty liver disease. BMC Med Genet. 2010; 11: 172.
7.
IwataR, BaurK, StiegerB, . Swiss Hepatitis C Cohort Study Group. A common polymorphism in the ABCBII gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clin Sci (Lond). 2011; 120: 287–296.
8.
CurtoTM, LagierRJ, LokAS, . Predicting cirrhosis and clinical outcomes in patients with advanced chronic C with a panel of genetic markers (CRS7). Pharmacogenet Genomics. 2011; 21: 851–860.
9.
BouzgarrouN, HassenE, BahriO, . Combined effect of pro and anti-inflammatory cytokine gene polymorphisms on susceptibility to liver cirrhosis in Tunisian HCV-infected patients. Hepatol Int. 2011; 5: 681–687.
10.
BordeWA, NobleNA. Mechanisms of disease: transforming growth factor-beta in tissue fibrosis. N Engl J Med. 1994; 331: 1286–1292.
11.
BrantonMH, KoppJB. TGF-beta and fibrosis. Microbes Inf. 1999; 1: 1349–1365.
12.
Gálvez-GastélumFJ, Sandoval-RodríguezAS, Armendáriz-BorundaJ. El factor de crecimiento transformante β como blanco terapéutico. Salud Pública Méx. 2004; 46: 341–350.
13.
DerynckR, RheeL, ChenEY, . Intron-exon structure of the human transforming growth factor beta precursor gene. Nucleic Acid Res. 1987; 15: 3188–3189.
14.
TagCG, MengsteabS, HellerbrandC, . Analysis of the transforming growth factor-β1 (TGF-β1) codon 25 gene polymorphism by LightCycler-analysis in patients with chronic hepatitis C infection. Cytokine. 2003; 24: 173–181.
15.
GewaltingJ, MangasserK, GartungC, . Association of polymorphisms of the transforming growth factor-beta 1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta. 2002; 316: 83–94.
16.
XaubetA, MarinA, LarioS, . Transforming growth factor b1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003; 168: 431–435.
17.
BatallerR, GinesP, NicolasJM, . Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000; 118: 1149–1156.
18.
BatallerR, Sancho-BruP, GinesP, . Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003; 125: 117–125.
19.
InoueI, NakajimaT, WilliamsCS, . A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and effects basal transcription in vitro. J Clin Invest. 1997; 99: 1786–1797.
20.
FriedmanSL. Hepatic fibrosis. In:SchiffER, ed.Schiff& die;s Diseases of the Liver, 9th ed.Philadelphia, PA: Lippincott Williams and Wilkins, 2003; 409–427.
RutterJL, MitchellTI, BautticeG, . Single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates and Ets binding site and augments transcription. Cancer Res. 1998; 58: 5321–5355.
23.
YeS, ErikssonP, HamstenA, . Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996; 271: 13050–13060.
24.
RidkerPM, GabouryCL, ConclinPR, . Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the rennin- angiotensin system and fibrinolytic function. Circulation. 1993; 87: 1969–1973.
25.
MansfieldMW, SticklandMH, GrantPJ, . Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non insulin-dependent diabetes mellitus. Thromb Haemost. 1995; 74: 842–847.
26.
MargaglioneM, CappucciG, d'AddeddaM, . PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants arteriosclerosis. Thromb Vasc Biol. 1998; 18: 562–567.
27.
IshakK, BaptistaA, BianchiL, . Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22: 696–699.
28.
MillerS, DykesD, PoleskyH. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16: 1215.
29.
Armendáriz-BorundaJ, RincónAR, Muñoz-ValleJF, . Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment. J Investig Med. 2008; 56: 944–953.
30.
WangH, MengsteabS, TagC, . Transforming growth factor-β1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol. 2005; 11 (13): 1929–1936.
31.
HahnAW, ResinkTJ, BernhardtJ, . Stimulation of autocrine platelet derived growth factor AA-homodimer and transforming growth factor beta in vascular smooth muscle cells. Biochem Biophys Res Commun. 1991; 178: 1451–1458.
32.
EurichD, BahraM, BoasS, . Transforming growth factor β1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus induced liver disease. Liver Transpl. 2011; 17: 279–288.
33.
AwadMR, El-GamelA, HasletonP, . Genotypic variation in the transforming growth factor β1 gene: association with transforming growth factor β1 production, fibrotic lung diseases, and graft fibrosis after lung transplantation. Transplantation. 1998; 66: 1014–1020.
34.
LachaJ, HubacekJA, PotmesilP, . TGF- beta I gene polymorphism in heart transplant recipients—effect on renal function. Ann Transplant. 2001; 6: 39–43.
35.
VerasER, CardenasL, GonzálezI, . Controlled clinical trial with pirfenidone in the treatment of breast capsular contracture. Ann Plast Surg. 2013; 70 (1): 16–22.
36.
SánchezR, GalavizC, SierraJA, . Polimorfismo 677CT del gen de la metilentetradihidrofolato reductasa y cardiopatías congenitas aisladas en población Mexicana. Rev Esp Cardiol. 2012; 65 (2): 158–163.
37.
ShinHP, LeeJI, JungJH, . Matrix metalloproteinase (MMP)-3 polymorphism in patients with HBV related chronic liver disease. Dig Dis Sci. 2008; 53: 823–829.
38.
OkamotoK, MimuraK, MurawakiY, . Association of functional gene polymorphisms of matrix metalloproteinase (MMP)-1, MMP-3 and MMP-9 with the progression of chronic liver disease. J Gastroenterol Hepatol. 2005; 20: 1102–1108.
39.
LaSpada E, SoresiM, GiannitrapaniL, . Long-term follow-up of hepatitis C virus-positive patients with persistently normal serum transaminases. Ann Hepatol. 2013; 12 (1): 36–43.
40.
PuotiC, GuariscoR, SpilabottiL, . Should we treat HCV carriers with normal ALT levels? The ‘5Ws’ dilemma. J Viral Hepat. 2012; 19: 229–235.
41.
FabrisC, FalletiE, CussighA, . The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. J Med Virol. 2012; 84: 747–755.
42.
KarpWB, SubramanyamSB, HoCK, . Drugs affecting bilirubin uptake by human erythrocyte ghosts. Am J Med Sci. 1985; 289 (6): 236–239.
43.
FeveryJ. Bilirubin in clinical practice: a review. Liver Int. 2008; 28 (5): 592–605.
